Compare
Lisata Therapeutics, Inc. vs Clene Inc. vs Serina Therapeutics, Inc. vs iBio, Inc.
| Latest fiscal year | Lisata Therapeutics, Inc. LSTA | Clene Inc. CLNN | Serina Therapeutics, Inc. SER | iBio, Inc. IBIO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-06-30 |
| Revenue | $170.0K | $200.0K | $130.0K | $100.0K |
| Revenue growth (YoY) | -83.0% | -41.5% | +132.1% | -75.0% |
| Gross margin | n/a | 78.5% (computed) | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$16.59M | -$26.17M | -$19.18M | -$33.04M |
| EPS (Diluted) | -$1.91 | n/a | -$1.91 | -$0.32 |
| Operating cash flow | -$15.95M | -$18.55M | -$17.95M | -$23.22M |
| Free cash flow | -$15.98M | -$18.59M | -$18.01M | -$23.80M |
| Cash & equivalents | $15.96M | $5.19M | $3.06M | $56.40M |
| Total assets | $17.74M | $18.13M | $6.95M | $99.11M |
| Total liabilities | $3.14M | $35.72M | $6.99M | $13.40M |
| Shareholders' equity | $14.86M | -$17.59M | -$37.0K | $85.71M |
| Return on year-end equity | -111.7% | n/a | n/a | -38.6% |
| Shares outstanding | 8.83M | 10.85M | 10.77M | 55.70M |
Revenue, most recent five fiscal years
| Fiscal year | Lisata Therapeutics, Inc. | Clene Inc. | Serina Therapeutics, Inc. | iBio, Inc. |
|---|---|---|---|---|
| Latest | $170.0K Ended 2025-12-31 | $200.0K Ended 2025-12-31 | $130.0K Ended 2025-12-31 | $100.0K Ended 2026-06-30 |
| 1 year earlier | $1.00M Ended 2024-12-31 | $342.0K Ended 2024-12-31 | $56.0K Ended 2024-12-31 | $400.0K Ended 2025-06-30 |
| 2 years earlier | $0 Ended 2023-12-31 | $654.0K Ended 2023-12-31 | $3.15M Ended 2023-12-31 | $225.0K Ended 2024-06-30 |
| 3 years earlier | $0 Ended 2022-12-31 | $473.0K Ended 2022-12-31 | $34.0K Ended 2022-12-31 | $0 Ended 2023-06-30 |
| 4 years earlier | n/a | $723.0K Ended 2021-12-31 | $144.0K Ended 2021-12-31 | $1.88M Ended 2022-06-30 |